17 December, 2024
Explore Creatio
CREATIO HAS BORN TO BOOST THE FIELD OF ADVANCED THERAPIES
Nowadays, diseases such as cancer, inflammatory diseases, autoimmune diseases and neurodegenerative diseases are a challenge that medicine must face. Currently, they have no cure or conventional treatments can only alleviate or delay symptoms. To offer new alternatives and seek a treatment for these diseases considered incurable, Advanced Therapy Medicines (ATMPs) are being developed. Advanced therapies are innovative medicines for human use that are based on genetic, cellular or human tissue modifications, offering an alternative to conventional medicines and therapies. These new therapies can provide personalized and more effective solutions.
In order to boost the field of advanced therapies in Catalonia, Creatio, production and validation center of advanced therapies at the University of Barcelona, has born. Creatio works to carry out basic research in advanced therapies for clinical use, with the aim to develop a more efficient health system and improve the quality of life of society. At this point, it is worth highlighting Creatio’s contribution to relevant projects to bring advanced therapies to the healthcare system, such as the ARI project and 4D-Bioskin. The ARI project was the first clinical trial authorized by the Spanish Agency for Medicines and Health Products (AEMPS) to use genetically modified cells in the treatment of lymphomas, a type of cancer. On the other hand, 4D-Bioskin is a pioneering project in Spain that will allow the first clinical trial to treat burns and skin wounds. Skin will be created through 3D bioprinting. In addition, between 2016 and 2019, Creatio produced the cellular vaccine for the HIV virus.
Furthermore, advanced therapies, like any other product in development, must be validated before being used in the clinical phases. In this sense, Creatio provides support in other phases of the drug development chain through regulatory preclinical studies. These studies are essential to ensure the safety and efficacy of any drug before starting a clinical trial with patients. Quality standards must be followed under good laboratory practices to ensure rigorous results and comply with specific regulations. In this line, Creatio is authorized to carry out its studies under good laboratory practices.
In addition, Creatio, apart from gathering experience in the production and validation of advanced therapies, also has a great deal of experience in the research of neurodegenerative diseases, especially Huntington’s disease. This disease is hereditary and there is still no cure. For these reasons, Creatio team is focused on finding out the mechanisms that affect the development of the nervous system to prevent the onset of the disease, as well as designing therapeutic solutions to cure it or mitigate its symptoms. Creatio team is developing alternative methods to the use of animals to investigate the disease, among which the microfluidics model such as the brain-on-chip stands out. This model is developed in collaboration with the IBEC. This human neuron culture system will be used to study the interactions between the different cells of the brain without using any living being.
Creatio collaborates with academic centers, hospitals, companies, and research institutes to bring science closer to the patient. Creatio is also committed to the goal of making science more accessible to society, participating in outreach activities and workshops to transfer the knowledge generated in laboratories to the population. In addition, the priority of Creatio is to train future researchers, encouraging the participation of staff in different courses and scientific conferences and thus promoting new talents. The progress achieved would not be possible without the dedication, commitment, and effort of the entire team, which is involved every day in the development of cutting-edge solutions that make advanced therapies and science accessible to the entire society in order to contribute to a healthier future.